Immutep Implodes: Why Biotech Valuations Are More Hype Than Reality
Immutep’s share plunge to AUD 0.02 exposes the volatility of biotech valuations, highlighting the gap between speculative hype and tangible clinical progress.
3 minutes to read
IMMUTEP LTD